Pembolizumab
Sponsors
Shanghai JMT-Bio Inc., Gruppo Oncologico del Nord-Ovest
Conditions
HER2-positive Gastric CancerHead & Neck Squamous Cell Carcinoma
Phase 2
JSKN003 Combined Treatment of HER2-positive Gastric Cancer
Not yet recruitingNCT06998771
Start: 2025-06-15End: 2029-12-31Target: 153Updated: 2025-05-31
A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer
Not yet recruitingNCT07332533
Start: 2025-12-30End: 2032-12-31Target: 490Updated: 2026-01-12
Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC)
RecruitingNCT07485296
Start: 2026-01-27End: 2032-12-01Target: 45Updated: 2026-03-20